This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcript

NeurogesX, Inc. (NGSX)

Q2 2012 Earnings Call

August 3, 2012 8:30 AM ET


Nicole Greenbaum – IR

Ronald Martell – President and CEO

Stephen Ghiglieri – EVP, COO and CFO



Greetings and welcome to the NeurogesX, Inc., Second Quarter 2012 Earnings Conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Nicole Greenbaum of the Ruth Group. Thank you, Ms. Greenbaum. You may now begin.

Nicole Greenbaum

Thank you operator. Joining us on the call today are Ronald Martell, President and Chief Executive Officer; Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer; Michael Markels, Senior Vice President, Commercial and Business Development; and Dr. Stephen J. Peroutka, Executive Vice President and Chief Medical Officer.

Statements in this conference call regarding NeurogesX’s business which are not historical facts may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 or the Act. NeurogesX disclaims any intent or obligation to update these forward-looking statements and claims protection of the Safe Harbor for forward-looking statements contained in the Act.

Forward-looking statements may include, but are not limited to, statements regarding expected quarterly cash usage rates for 2012, expectations and timing with respect to our entering NGX-1998 into Phase 3 clinical trial; the potential timeline of development of NGX-1998; and End-of-Phase 2 meeting with the FDA for NGX-1998 and expected areas of focus and benefits from such meetings and interactions with the FDA, securing and development partner for NGX-1998, the sufficiency of cash to fund operations well into 2013, expected reduced revenues from Qutenza commercialization efforts and expectations respect to such commercialization efforts, the benefits of NGX-1998 including as compared to Qutenza and its potential market advantage, and potential participation of our commercial partner in development of NGX-1998.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs